Page last updated: 2024-08-21

4-nitrophenyl acetate and Kidney Failure, Chronic

4-nitrophenyl acetate has been researched along with Kidney Failure, Chronic in 1 studies

*Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Furukubo, T; Hojo, A; Izumi, S; Katsube, Y; Koide, H; Minegaki, T; Nishiguchi, K; Ochiai, M; Shima, D; Tsujimoto, M; Yamakawa, T1

Other Studies

1 other study(ies) available for 4-nitrophenyl acetate and Kidney Failure, Chronic

ArticleYear
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:6

    Topics: Carboxylesterase; Case-Control Studies; Fatty Acids; Humans; Irinotecan; Kidney Failure, Chronic; Microsomes, Liver; Nitrophenols; Topoisomerase I Inhibitors; Uremia

2018